Randomized phase III double blind trial evaluating selective COX-2 inhibition in COX-2 expressing advanced non-small cell lung cancer

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://clinicaltrials.gov/ct2/show/NCT01041781

2. Intervention

   Carboplatin

3. Intervention

   Celecoxib

4. Intervention

   Gemcitabine hydrochloride

5. Intervention

   Pemetrexed disodium

6. Additional Topic(s)

   Antineoplastic combined chemotherapy protocols

7. Resource Description

   RATIONALE: Pemetrexed disodium and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving gemcitabine hydrochloride or pemetrexed disodium together with carboplatin is more effective with or without celecoxib in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying gemcitabine hydrochloride, pemetrexed disodium, and carboplatin to compare how well they work when given together with celecoxib or a placebo in treating patients with advanced non-small cell lung cancer.

8. Contact

   Berenberg, Jeffrey

9. PI

   Berenberg, Jeffrey

10. Topic

    lung cancer

11. Study Population

    Males and females aged 18 and older with histologically or cytologically confirmed non-small cell carcinoma of the lung, including the following cell types: adenocarcinoma, large cell carcinoma, squamous cell carcinoma, or a mixture of these types.

12. Website(s)

    http://www.cancer.gov/clinicaltrials/search/view?cdrid=662707&version=healthprofessional

13. Funded by

    Cancer Trials Support Unit

14. Phase

    Phase 3 clinical trial

15. Performed by

    Clinical Protocol & Data Management Shared Resource